# Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

> **NCT03668054** · PHASE3 · COMPLETED · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 22 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Bevacizumab (Lumiere®)

## Key facts

- **NCT ID:** NCT03668054
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-07
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-05-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03668054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03668054, "Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03668054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*